Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ferring Pharmaceuticals, part of the Ferring Group, has promoted William Garbarini, Jr to vice president of its new orthopedics and urology business unit, recently formed by merging these clinical product areas. Mr Garbarini was formerly executive director of Ferring's orthopedics business unit.
Subscribe to our email newsletter
In his new role, Mr Garbarini is responsible for Ferring’s two marketed products in these areas, euflexxa (1% sodium hyaluronate) for the pain caused by knee osteoarthritis, and Prosed DS for the relief of discomfort of the lower urinary tract. He will also oversee the US sales and marketing of Ferring’s pipeline of urology products, including a GnRH antagonist for prostate cancer.
Prior to joining Ferring, Garbarini was director, client services for Caresoft. Previously, he served in various positions at Schering-Plough/Key Pharmaceuticals, Lowe McAdams Healthcare advertising agency, and Glaxo Wellcome, where he was honored as a top sales representative.
Wayne Anderson, president of Ferring, said: “Bill’s talent, leadership and wealth of experience in pharmaceutical marketing have driven his rapid rise and recognition in the healthcare industry. After spearheading the growth of our infertility and orthopaedics businesses, he is extremely qualified to lead our new orthopaedics and urology unit.”